Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 819

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 819
---
. The
Company understands due to multiple rounds of financing and debt conversions to equity, there may have been an ownership change under Section 382. The Company plans to perform a Section 382 Analysis in the future when it is relevant. Due
to the full valuation allowance, a Section 382 Analysis is not relevant at this time.

In assessing the realization of deferred tax
assets, management considers whether it is more likely than not that some portion or all the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable
income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment.
Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31,
2024 and 2023.

There was income tax expense for the years ended December 31, 2024 and 2023 of $3,768 and $0, respectively.

Note 12-Stockholders’equity

Immediately prior to the closing of the Merger, all outstanding shares of Company preferred stock were converted into shares of Company common
stock (which were converted into shares of Kintara common stock in the Merger), and upon completion of the merger, all warrants of the Company were converted into warrants to purchase Kintara common stock. All outstanding shares of the
Company’s Preferred Stock were converted into 16,912,843 shares of common stock.

As of December 31, 2024, the Company had two
classes of stock defined in its Amended and Restated Articles of Incorporation (the “Articles).

Common Stock - The Company is
authorized to issue up to 75,000,000 shares of Common Stock based on the Articles. Holders of common stock are entitled to one vote for each share of common stock. As of December 31, 2024, there were 42,323,759 shares of common stock
outstanding, of which 4,730 are unregistered shares of warrants exercised after the merger.

Preferred Stock - The Company is
authorized to issue up to 5,000,000 shares of Preferred Stock based on the Articles.

The historical Kineta Series A Preferred Stock were
assumed from the merger and outstanding and have a stated value of $278,530 as of